**Appendix 1: Prevalence of gabapentinoid pre-admission use from December 2013 to July 2017a**



aJanuary to March = q1; April to June = q2; July to September = q3; October to December = q4.

**Appendix 2: Indications for new gabapentinoid prescriptions at dischargea**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Total** N=48b | **Gabapentin**N=11 | **Pregabalin** N=37 |
| **Indications** |  |  |  |
| **Neuropathic pain disorders** |
| Neuropathic pain, not otherwise specified | 18 (37.5) | 3 (27.3) | 15 (40.5) |
| Diabetic Neuropathic Pain | 4 (8.3) | 1 (9.1) | 3 (8.1) |
| Postherpetic neuralgia | 4 (8.3) | 1 (9.1) | 3 (8.1) |
| Spinal cord injury neuropathic pain | 0 (0) | 0 (0) | 0 (0) |
| **Musculoskeletal and other nociceptive pain disorders** |
| Musculoskeletal pain | 8 (16.7) | 2 (18.2) | 6 (16.2) |
| Cancer-associated pain | 6 (12.5) | 2 (18.2) | 4 (10.8) |
| **Other** |
| Not specified | 3 (6.3) | 0 (0) | 3 (8.1) |
| Diabetes mellitus, neuropathic pain not documented | 3 (6.3) | 0 (0) | 3 (8.1) |
| Alcohol use disorder | 2 (4.2) | 2 (18.2) | 0 (0) |
| Total | 48 (100) | 11 (100) | 37 (100) |

aAll data are given as number (percentage) unless otherwise indicated

bTotal of 48 patients includes 3 patients for whom there was a gabapentinoid class change at discharge

**Appendix 3. Indication for gabapentinoid deprescribing at discharge among pre-admission usersa**

|  |  |
| --- | --- |
| **Indication for discontinuation (N=69b)** | No. (%) |
| Adverse drug reaction | 15 (21.7) |
| Absence of indication | 6 (8.7) |
| Change to another gabapentinoid or duplication of therapyb | 4 (5.8) |
| Being tapered prior to admission | 2 (2.9) |
| Absence of efficacy | 1 (1.4) |
| Other | 3 (4.3) |
| Unknown/reason for discontinuation not documented | 38 (55.1) |
| Total | 69 (100) |

aAll data are given as number (percentage) unless otherwise indicated

b Total of 69 patients includes 3 patients for whom there was a gabapentinoid class change at discharge and 1 patient who was taking 2 gabapentinoids pre-admission, with only 1 continued at discharge.

**Appendix 4. Prevalence of gabapentinoid deprescribing among pre-admission users from December 2013 to July 2017a**



aJanuary to March = q1; April to June = q2; July to September = q3; October to December = q4. Excludes patients who died during admission.